CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioMark Diagnostics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioMark Diagnostics Inc
130 - 3851 Shell Rd
Phone: (604) 836-6950p:604 836-6950 RICHMOND, BC  V6X 2W2  Canada Ticker: BUXBUX
Business Summary
BioMark Diagnostics Inc. is a developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The Company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. It is also engaged in developing accessible diagnostic solutions to address unmet medical needs in oncology. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a liquid biopsy metabolic panel assay, which is instrumental for early-stage diagnosis of lung cancer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20243/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
8071 Medical laboratories

Business Names
Business Name
20B
Biomark Cancer Systems Inc.
BUX

General Information
Outstanding Shares: 105,090,213 (As of 4/1/2025)
Stock Exchange: CNQ
Fax Number: (604) 836-6950


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 18, 2025